The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 10, 2020

Filed:

May. 24, 2018
Applicant:

Ultupharma Ab, Uppsala, SE;

Inventors:

Bo Öberg, Uppsala, SE;

Anders Broberg, Uppsala, SE;

Bengt Guss, Uppsala, SE;

Jolanta Levenfors, Orbyhus, SE;

Joakim Bjerketorp, Uppsala, SE;

Christina Nord, Uppsala, SE;

Assignee:

Ultupharma AB, Uppsala, SE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/04 (2006.01); A61K 31/70 (2006.01); A61K 31/7072 (2006.01); A61K 31/505 (2006.01); A61K 45/06 (2006.01); A61K 31/635 (2006.01); A61K 31/708 (2006.01); A61P 31/04 (2006.01); A61K 9/00 (2006.01); A61K 31/506 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7072 (2013.01); A61K 9/0053 (2013.01); A61K 31/505 (2013.01); A61K 31/635 (2013.01); A61K 31/708 (2013.01); A61K 45/06 (2013.01); A61P 31/04 (2018.01); A61K 31/506 (2013.01); A61K 2300/00 (2013.01); Y02A 50/30 (2018.01);
Abstract

The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be iclaprim; trimethoprim; or a compound comprising trimethoprim, such as trimethoprim-sulfa.


Find Patent Forward Citations

Loading…